Zimbabwe has turned down a significant American healthcare agreement worth $367m (£272m) over five years due to the United States' request for sensitive biological samples.
The decision was revealed after a government memo dated December was leaked, which showed President Emmerson Mnangagwa felt the agreement was "lopsided".
An official spokesperson has since explained that the United States was requesting genetic material for scientific study and commercial purposes but was unwilling to share the benefits from any future treatments.
"We are forced to start the challenging and unfortunate task of ending our health aid in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had provided more than $1.9bn for health programmes to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has called for more dialogue to find a agreement acceptable to all parties so the country's vital HIV treatment initiative can proceed.
Wider Implications
This rejection follows a similar case in Kenya, where a court halted a similar health funding agreement after legal challenges were filed about the safety of Kenyans' medical information.
Since resuming office recently, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
USAID had managed aid for the US government, but Trump claimed its expenditure was "inefficient" and his government was seeking direct bilateral agreements to boost transparency and accountability.
According to statements, Sixteen nations in Africa have to date agreed to similar agreements, representing more than $18.3bn of fresh investment.
Details of the Declined Agreement
The funds for Zimbabwe would have funded "combating HIV/Aids, TB, malaria, maternal and child health, and preparing for epidemics".
"It is our view this cooperation could have provided significant advantages for the people of Zimbabwe, especially the 1.2 million currently on HIV treatment through American-funded initiatives," Tremont added.
However, government spokesperson Nick Mangwana argued the arrangement was "asymmetrical".
"The proposal required Zimbabwe to provide its biological resources and data over an extended period, with no corresponding guarantee of access to any medical innovations – like vaccines, diagnostics, or treatments – that could result from that provided information," Mangwana explained.
"Effectively, our nation would provide the basic resources for medical research without any assurance that the resulting innovations would be available to our people should a new health crisis arise."
National Interest and International Frameworks
He also said that the US's withdrawal from the global health body and its push of bilateral health agreements were undermining frameworks already established via the global organization.
Mangwana gave as an example its Pandemic Benefit-Sharing framework created to manage potential pandemics.
"This framework is designed to ensure that when a country contributes its data, the benefits – including medicines and cures – are shared equitably, not commercialised solely by those with the funds to create them."
The government's concerns regarding the US deal "must not be interpreted as anti-American sentiment," he added.
"We welcome further discussions with our US partners on how subsequent co-operation might be structured in a way that honours the independence and dignity of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the government's concerns, but urged that negotiations should continue considering much of the nation's HIV programmes depended on external financing.
"In cases where specific concerns arise, such as those involving information security or implementation frameworks, these can often be addressed through detailed discussion and mutually agreed protections," it added.
The halted deal emphasises the complex tensions between accepting much-needed international aid and safeguarding local interests in an ever more interconnected world.